Saturday, September 13, 2008
Bestech Australia offer DEMEC Mechanical Strain Gauge, a single instrument which can take reliable and accurate strain measurements at different points on a structure.
The DEMEC Mechanical Strain Gauge is developed by Mayes Instruments and has gauge lengths of 50 to 2000mm and a discrimination of two microstrains on the 200mm gauge.
This makes the DEMEC Mechanical Strain Gauge suitable for strain measurement and crack monitoring on many different types of structures.
The DEMEC Mechanical Strain Gauge consists of an invar main beam with two conical locating points, one fixed and the other pivoting on a special knife edge. The points sit in pre-drilled stainless steel discs, which are attached to the structure with adhesive.
The pivoting point’s movements are measured by the strain gauge, which is attached to a base plate on the invar beam. Thermal movement within the instrument is negligible.
With practice, 200 strains per hour can be measured with accuracy of about ±5 x 10-6 under most laboratory test conditions.
Even better accuracy has been obtained using the gauge in its horizontal position. In development tests of this kind, 90% of measured strains were within ±3 x 10-6 of the mean.
The digital version of the DEMEC Mechanical Strain Gauge incorporates a digital indicator with a resolution of 0.001mm, zero set, preset and output for SPC.
The indicator can be connected to a data processor for recording and analysis of results. The indicator displays spindle movement digitally by means of a linear encoder and has a response speed of 1000mm per second. The digital DEMEC is battery operable.
The DEMEC Mechanical Strain Gauge come complete with an invar reference bar, for control measurements and a setting out bar for accurate positioning of locating discs.
Bestech provides the latest in measurement and control technology to the Australian and NZ market. We are focused to meet the instrumentation needs of customers in: Research & Education, Automotive, Metal Industry, Automation, Defence, Mining, General Manufacturing, Food Beverage, Water/wastewater, Chemical, Oil & Gas, Pulp & paper.
Bestech Australia Products & Services
Temperature And Pressure Test And Measurement
Electronic Design Software
Non Destructive Testing
Bulk Material Weighing
The Food and Drug Administration reported, on Thursday, of the death of a woman who developed a rare brain disorder about 18 months after taking the final prescribed dosage of Genentech and Biogen Idec's Rituxan.
The FDA has advised the doctors to look for any neurological problems in patients taking Rituxan.
A company spokeswoman for Genentech remarked that the drug's label already states risks of the infection.
"The patient had a number of confounding factors that make it difficult to assess the potential role, if any, that Rituxan exposure may have played," said Tara Cooper. She further said that Genentech first disclosed the death during its July earnings call.
Rituxan, a blockbuster drug for arthritis and cancer, is marketed by Genentech and Biogen Idec in the U.S.
Both Rituxan and Tysabri multiple sclerosis drug, which reportedly also triggered the brain disorder in rare cases, are built on antibodies that maneuver the immune system.
FDA reported that the patient who died while on Rituxan had also received chemotherapy agents about nine months earlier.
Shares of Genentech Inc. rose $1.08 Thursday to $96.77 in afternoon trading. Shares of Biogen Idec Inc. fell 18 cents to $47.12.